Sign In
Buy SNANF
$0.211
+0.0055 (+2.68%)
At Close: Jun 02, 2026
Sona Nanotech Reports 80% Response Rate in First-In-Human THT Cancer Therapy Study
06:00am, Monday, 20'th Oct 2025
-- Six out of ten patients experienced complete responses in treated tumors with an additional two patients demonstrating partial responses - confirmed in a representative tumor biopsy - all within tw
Sona Nanotech To Host Investor Webinar To Discuss Clinical Study
04:04pm, Friday, 17'th Oct 2025
Halifax, Nova Scotia--(Newsfile Corp. - October 17, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), announces that it will host a webinar on Monday, October 20th at noon
Sona Nanotech advances first-in-human cancer therapy trial
09:54am, Monday, 25'th Aug 2025
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) announced that it has completed treatment and follow-up assessments for the first cohort of patients in its early feasibility study of Targeted Hyperthermia T
Sona Provides Update on First-In-Human Clinical Trial
09:14am, Monday, 25'th Aug 2025
Halifax, Nova Scotia--(Newsfile Corp. - August 25, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative therap
Sona Nanotech launches first human trial for groundbreaking cancer therapy
08:58am, Friday, 01'st Aug 2025
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF), a clinical-stage biotech company specializing in nanotechnology-driven cancer treatments, has reached a significant milestone with the initiation of its firs
Sona Nanotech gains ethics nod for cancer trial - ICYMI
08:23am, Saturday, 26'th Jul 2025
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) CEO David Regan talked with Proactive about the company's recent ethics committee approval for a pilot cancer study. This approval represents the next step in
Sona Nanotech gets ethics board nod for pilot melanoma cancer trial in Canada
08:54am, Wednesday, 23'rd Jul 2025
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) said on Wednesday it has received approval from Nova Scotia's Health Research Ethics Board to proceed with a pilot human clinical trial of its gold nanorod-ba
Sona Announces Canadian Melanoma Clinical 'Pilot' Study Ethics Approval
06:00am, Wednesday, 23'rd Jul 2025
Halifax, Nova Scotia--(Newsfile Corp. - July 23, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative therapie
Sona Nanotech begins clinical trial for late-stage cancer – ICYMI
04:33pm, Friday, 11'th Jul 2025
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) CEO David Regan talked with Proactive about the company's first-in-human clinical trial using its THT therapy for late-stage melanoma patients. Regan explaine
Sona Nanotech doses first patient in cancer therapy feasibility study
09:53am, Monday, 07'th Jul 2025
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) announced that it has dosed the first patient in an early feasibility study of its Targeted Hyperthermia Therapy (THT) cancer treatment. The study is evaluati
First Patient Dosed in Early Feasibility Study Trial of its Cancer Therapy
09:18am, Monday, 07'th Jul 2025
Trial is expected to provide key insights on safety, tolerability and immune system response for its THT treatment of late-stage melanoma patients Halifax, Nova Scotia--(Newsfile Corp. - July 7, 2025)
Sona Nanotech gets ethics committee nod to launch early-stage cancer therapy trial
09:04am, Friday, 27'th Jun 2025
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) said it has received ethics committee approval to begin enrolling patients in an early feasibility study for its Targeted Hyperthermia Therapy (THT), a novel
Sona Announces Ethics Committee Approval For Melanoma Clinical Trial
08:45am, Friday, 27'th Jun 2025
Halifax, Nova Scotia--(Newsfile Corp. - June 27, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative therapie
Sona Nanotech signs Chile trial partner for targeted hyperthermia therapy trial - ICYMI
11:24am, Saturday, 21'st Jun 2025
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) CEO David Regan talked with Proactive about the company's latest step in advancing its targeted hyperthermia therapy (THT) towards market approval. Speaking f
Sona Nanotech engages clinic for first-in-human trial of THT cancer therapy
09:10am, Monday, 16'th Jun 2025
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) announced that it has entered into a clinical trial agreement for an early feasibility study of its Targeted Hyperthermia Therapy (THT) in advanced melanoma p
